Comparing the effects of continuing or stopping metformin during hospital stays for diabetes patients
Effect of Continuing Versus Holding Metformin During Hospitalizations to Internal Medicine on Glucose Control, Acidosis, Abdominal Symptoms, Length of Stay, and Mortality.
This study is testing whether keeping patients on metformin or stopping it during their hospital stay helps people with type 2 diabetes manage their blood sugar better and stay healthier.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 110 Years |
| Sex | All |
| Sponsor | University of Illinois at Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06296836 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of continuing versus holding metformin in hospitalized patients with type 2 diabetes. It is a randomized trial that aims to assess various outcomes, including glucose control, incidence of lactic acidosis, gastrointestinal symptoms, length of hospital stay, and 30-day mortality rates. The research will involve adult patients admitted to internal medicine services who were on metformin prior to their hospitalization. By analyzing these outcomes, the study seeks to provide insights into the best practices for managing diabetes medications during hospital stays.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are admitted to an internal medicine service and were taking metformin before their hospitalization.
Not a fit: Patients who are unable to take oral medications, have severe renal impairment, or are experiencing acute acidosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of diabetes in hospitalized patients, potentially reducing complications and improving recovery outcomes.
How similar studies have performed: Other studies have explored the management of diabetes medications during hospitalization, but this specific comparison of continuing versus holding metformin is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (18+ years of age) * Admitted to an internal medicine service. * On Metformin prior to admission. Exclusion Criteria: * Inability to take oral medications * eGFR \< 30 ml/min/1.73 m2 * Dialysis * Current Acidosis (pH \< 7.35) including diabetic ketoacidosis * Child-Turcotte-Pugh class C hepatic cirrhosis * Acute Decompensated Heart Failure * Cognitively impaired and/or unable to consent * Lack of or unwillingness to share contact information * Pregnant women
Where this trial is running
Chicago, Illinois
- University of Illinois at Chicago — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Mathew Thambi, PharmD, MPH
- Email: mthambi@uic.edu
- Phone: 312-497-5540
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.